DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
N••••••• T•••••••••
Drug Discovery & Developmentgroup grade Aon a schedule nowsponsor unattributed
Also written as: 12; 12/15/2021; 15; 2021; Convertible Debt; Convertible Debt and; December 2026; Equity
What matters now
- $473Kprincipal outstanding
$473K principal held by 1 lender; matures Jun 2027.
Q2 2026 · Refinancing is due in 8 months at a 100¢ mark.
FactBDC schedules of investments, 30 Jun 2026; a sum of the BDCs' pieces, a lower bound
Mark path, consensus per quarter end
100¢ · 100¢ · 100¢ · 100¢ · 100¢Q2 2025 to Q2 2026
Principal held
at least $473,000
sum of BDC pieces, a lower bound
Fair value
$1.1M
100c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
1 equity pieces beside them
Next maturity
Jun 1, 2027
$473,000 inside 24 months
On the tape since
Dec 31, 2022
latest Jun 30, 2026
Events
3
dated, non-routine
Lender marks
each lender's own fair value over cost at Jun 30, 2026, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| H••••••• C••••••• I••• | $473K | 100¢ | 0 pts |
Every BDC piece · 2 positions across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | unstated lien unstated 6.00% | $473,000 | $473,000 100c | |
| H••••••• C••••••• I••• | preferred equity equity P•••••••• Series C | Not disclosed | $623,000 31c |
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| other lien unstated | at least $473,000 | 100c | Jun 1, 2027 | 1 |
Equity pieces beside the debt: preferred equity ($623,000 fair value, 1 BDC)
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $473,000 | $473,000 | 100c | 0 |
| Mar 31, 2026 | 1 | $373,000 | $373,000 | 100c | 0 |
| Dec 31, 2025 | 1 | $373,000 | $373,000 | 100c | 0 |
| Sep 30, 2025 | 1 | $373,000 | $373,000 | 100c | 0 |
All 15 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2025 | 1 | $273,000 | $273,000 | 100c | 0 |
| Mar 31, 2025 | 1 | $273,000 | $273,000 | 100c | 0 |
| Dec 31, 2024 | 1 | $273,000 | $273,000 | 100c | 0 |
| Sep 30, 2024 | 1 | $273,000 | $273,000 | 100c | 0 |
| Jun 30, 2024 | 1 | $0 | $0 | n/a | 0 |
| Mar 31, 2024 | 1 | $0 | $0 | n/a | 0 |
| Dec 31, 2023 | 1 | $0 | $0 | n/a | 0 |
| Sep 30, 2023 | 1 | $0 | $0 | n/a | 0 |
| Jun 30, 2023 | 1 | $0 | $0 | n/a | 0 |
| Mar 31, 2023 | 1 | $0 | $0 | n/a | 0 |
| Dec 31, 2022 | 1 | $0 | $0 | n/a | 0 |
What changed
- Maturity approachingJun 1, 2027
- Maturity approachingJun 1, 2027
- Maturity approachingJun 1, 2027
- Maturity extended (observed)Jun 30, 2026
- Maturity extended (observed)Sep 30, 2025
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- N••••••• T•••••••••derivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it